AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37708629
Drug: Apalutamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide plus androgen-deprivation therapy (ADT)
Trial: 37708912
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus HIPEC (100 mg/m²)
Trial: 37709280
Drug: Dexamethasone 24
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 24 mg + placebo (DX1)
Trial: 37709280
Drug: Dexamethasone 24
RxNorm normalized name: dexAMETHasone 24 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 24 mg + dexamethasone 24 mg (DX2)
Trial: 37709305
Drug: ACT for
RxNorm normalized name: sodium fluoride Mouthwash [ACT Fluoride Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT for informal caregiver (ACT-IC) intervention delivered over a 9-week period consisting of a collaborative goal-setting session, nine online ACT modules, nine telephone-based motivational coaching sessions and 6 monthly booster sessions following the main intervention period.
Trial: 37709311
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of oral vancomycin every 6 hours for 10 days
Trial: 37709314
Drug: nCRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCRT + immunotherapy
Trial: 37709320
Drug: Intravenous sivelestat
RxNorm normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Intravenous sivelestat sodium for up to 7 days
Trial: 37709337
Drug: Powdered meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered meal replacement (PMR) group: replacing morning and afternoon snacks daily with a PMR for 12 weeks
Trial: 37709661
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550 (9 mg or 18 mg)
Trial: 37710005
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel) as second-line therapy
Trial: 37710178
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of lipid lowering therapy
Trial: 37710198
Drug: Low-dose tamoxifen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tamoxifen (5 mg/day) for 5 years
Trial: 37710376
Drug: Suboptimal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal protein intake (0.2 g·kg-1·d-1)
Trial: 37710376
Drug: Moderate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate protein intake (1.2 g·kg-1·d-1)
Trial: 37710376
Drug: Excess protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excess protein intake (2.0 g·kg-1·d-1)
Trial: 37710376
Drug: Recommended protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended protein intake for males (1.81 g·kg-1·d-1)
Trial: 37710376
Drug: Recommended protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended protein intake for females (1.89 g·kg-1·d-1)
Trial: 37710376
Drug: Upper 95%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper 95% confidence interval protein intake (~1.85 g·kg-1·d-1)
Trial: 37711193
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg on day 1, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg on day 22, and nivolumab 3 mg/kg on day 43 followed by chemoradiation
Trial: 37711198
Drug: Inhaled iloprost
RxNorm normalized name: iloprost Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled iloprost (5ug), QID dosing
Trial: 37711623
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with ITI-3000 (a cancer vaccine targeting MCPyV-LT)
Trial: 37712585
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B birth dose along with routine immunisation vaccines
Trial: 37712728
Drug: Maximal expiratory
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal expiratory pressure during induced cough (measured with slow instillation of 2mL of a 0.9% saline solution)
Trial: 37712908
Drug: Eculizumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab treatment for >35 days
Trial: 37712984
Drug: Antiresorptive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive therapy (ART)
Trial: 37713020
Drug: Relugolix (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix (120 mg orally once daily after single 360 mg loading dose)
Trial: 37713020
Drug: Relugolix with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix with concomitant CV agents
Trial: 37713527
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g intravenous cefoxitin
Trial: 37713598
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of WJ-MSC and Magnovision
Trial: 37713684
Drug: Ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor and clopidogrel on top of aspirin (ADAPT)
Trial: 37715029
Drug: Anti-PD-1 therapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 therapy with thyroid dysfunction
Trial: 37715173
Drug: Intravenous opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioid
Trial: 37715249
Drug: BCN-led group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCN-led group cognitive behavioural therapy (CBT)
Trial: 37715270
Drug: Quizartinib combined
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib combined with high-dose Ara-C plus mitoxantrone (HAM)
Trial: 37715270
Drug: Intensive salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive salvage therapy
Trial: 37715730
Drug: Indoximod-based combination
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoximod-based combination therapy with oral temozolomide (200 mg/m2/day x 5 days in 28-day cycles)
Trial: 37715730
Drug: Indoximod-based combination
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoximod-based combination therapy with palliative conformal radiation
Trial: 37715730
Drug: Indoximod-based combination
RxNorm normalized name: Indoximod
DrugBank: Indoximod (DB12827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoximod-based combination therapy
Trial: 37715767
Drug: Youth Development
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Youth Development Accounts (YDA) treatment, n=471 girls
Trial: 37715860
Drug: Pegcetacoplan treated
RxNorm normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegcetacoplan treated monthly (PM)
Trial: 37716204
Drug: ACT-IN plus
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-IN plus treatment as usual (TAU)
Trial: 37716204
Drug: TAM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAM plus treatment as usual (TAU)
Trial: 37716365
Drug: Bivalent SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent SARS-CoV-2 recombinant protein vaccine (5 μg of ancestral [D614] and 5 μg of beta [B.1.351] variant spike protein, with AS03 adjuvant), administered as two 0.5 mL intramuscular injections, 21 days apart.
Trial: 37716365
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% normal saline), administered as two 0.5 mL intramuscular injections, 21 days apart.
Trial: 37716448
Drug: DAPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT plus rivaroxaban 2.5mg twice daily for 4 weeks
Trial: 37716893
Drug: Brief Cognitive-Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief Cognitive-Behavioural Therapy (CBT) intervention, six sessions
Trial: 37716990
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rapid diagnostic testing and pharmacist-led de-escalation
Trial: 37716990
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with anti-viral medications
Trial: 37716990
Drug: Total duration
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total duration of any antibiotic
Trial: 37717638
Drug: SHHC-2.0 intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHHC-2.0 intervention (24 weeks of twice-weekly experiential nutrition education and group-based physical activity classes)
Trial: 37717786
Drug: Hypofractionated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated proton beam radiation therapy (PBT) at dose level 1 (DL1) - 5 Gy × 5 fractions, administered on days 15 to 19 in a 28-day cycle before starting cycle 7 of mFFX.
Trial: 37717786
Drug: Hypofractionated proton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated proton beam radiation therapy (PBT) at dose level 2 (DL2) - 5 Gy × 5 fractions, administered on days 8 to 12 in a 21-day cycle before starting cycle 7 of mFFX.
Trial: 37718234
Drug: Technetium-99m-mercaptoacetyltriglycine diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technetium-99m-mercaptoacetyltriglycine diuretic renography at timepoint 1
Trial: 37718721
Drug: Pegozafermin 27
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 27 mg once weekly for 20 weeks
Trial: 37718930
Drug: Mini-dose Bier's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-dose Bier's block
Trial: 37719091
Drug: Increased physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased physical activity (500 steps/day weekly until 10,000 steps/day)
Trial: 37719417
Drug: BCG-Denmark vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-Denmark vaccination (1 intradermal dose of 0.1 mL)
Trial: 37720013
Drug: BRIGHT (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRIGHT (5 weekly psychologist-led video tele-CBT sessions)
Trial: 37720013
Drug: Attention Control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Control (dose-and delivery matched survivorship education)
Trial: 37720456
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - eight sessions of group-based CBT (every 2-3 weeks)
Trial: 37720540
Drug: Sensor Augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor Augmented Pump (SAP) therapy
Trial: 37720540
Drug: Multiple Daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Daily Injection (MDI) therapy
Trial: 37720564
Drug: Omadacycline treatment
RxNorm normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omadacycline treatment at 16× the MIC for 72 hours
Trial: 37720591
Drug: Mobile app-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app-based self-guided psychological intervention (Nałogometr) delivered via smartphone app for four weeks, including mindfulness and cognitive behavioral therapy modules.
Trial: 37720695
Drug: Early 75 g
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early 75 g OGTT at 12-15 weeks of gestation
Trial: 37720695
Drug: Lowering postload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowering postload glucose values (75 g OGTT cut-off values of 5.1, 8.9, and 7.8 mmol/L)
Trial: 37721470
Drug: Adjunctive COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive COX-2 inhibitor etoricoxib
Trial: 37721581
Drug: novel somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel somatostatin receptor (SSTR) antagonist
Trial: 37721754
Drug: Cetuximab maintenance
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab maintenance therapy after FOLFIRI plus cetuximab induction therapy
Trial: 37721754
Drug: Observation after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation after FOLFIRI plus cetuximab induction therapy
Trial: 37721786
Drug: 12-week tele-RHB
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week tele-RHB program along with CPAP therapy
Trial: 37721786
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy alone
Trial: 37721786
Drug: tele-RHB program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tele-RHB program and CPAP therapy
Trial: 37721791
Drug: AT-Patch device
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-Patch device
Trial: 37721795
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light (BL) therapy
Trial: 37721795
Drug: Dim Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim Light (DL) therapy
Trial: 37721964
Drug: Triple drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple drug treatments (IDA, MoxDA)
Trial: 37721990
Drug: Oral Δ
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Δ
Trial: 37722354
Drug: ibrutinib +
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ibrutinib + CIT (560 mg daily plus 6 cycles of BR/R-CHOP)
Trial: 37722354
Drug: placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo + CIT (placebo daily plus 6 cycles of BR/R-CHOP)
Trial: 37722662
Drug: Integrated malaria-helminth
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated malaria-helminth treatment approach
Trial: 37723108
Drug: Remotely administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely administered adherence programme
Trial: 37723272
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient treatment (ST)
Trial: 37723467
Drug: Standard prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prophylactic medication
Trial: 37725026
Drug: Standard whole-gland
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard whole-gland radiation therapy of 77 Gy
Trial: 37725234
Drug: 2.9 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.9 mm diameter bone-level-tapered implant
Trial: 37725613
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose physical therapy intervention initiated in the NICU and continuing to 12 months of age, with twice-weekly sessions and caregiver-guided activities
Trial: 37725680
Drug: Nesiritide treatment
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide treatment in decompensated heart failure
Trial: 37725919
Drug: Patiromer (8.4-33.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (8.4-33.6 g/day for 12 months)
Trial: 37726068
Drug: Miracle fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miracle fruit (MF) tablet
Trial: 37726695
Drug: Atezolizumab (PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (PD-L1 directed immunotherapy, IV infusion, 1680 mg, every 28 days for one year if tolerated)
Trial: 37726695
Drug: Atezolizumab (PD-L1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (PD-L1 directed immunotherapy)
Trial: 37726771
Drug: Education Outside
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education Outside the Classroom (EOtC) intervention: a two-day training course for teachers followed by implementation of EOtC >5 hours weekly over one school year.
Trial: 37726786
Drug: Patient-derived tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-derived tumor organoids (PDTO) cultured in a medium supplemented with growth factors and signal pathway inhibitors.
Trial: 37726786
Drug: PDTO response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PDTO response to chemo-ICB (immune checkpoint blocker and chemotherapy).
Trial: 37726820
Drug: Plant-based omega
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant-based omega fatty acid supplement
Trial: 37726820
Drug: Both supplements
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both supplements combined
Trial: 37726823
Drug: BNI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNI plus facilitated initiation of medications for alcohol use disorder (BNI + MAUD)
Trial: 37726823
Drug: BNI +
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BNI + MAUD + initiation of computer-based training for cognitive behavioral therapy (CBT4CBT)
Trial: 37727387
Drug: Intraoperative slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative slow-release dexamethasone intravitreal implant (Ozurdex)
Trial: 37727387
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dexamethasone implant)
Trial: 37728115
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors (TKIs)
Trial: 37728142
Drug: Digital self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital self-help plus treatment as usual (TAU)
Trial: 37728224
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone furoate 50 μg once daily (QD)
Trial: 37728392
Drug: Breast implants
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast implants
Trial: 37728696
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (including MPFF, diosmin, compression stockings, creams)
Trial: 37728696
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (including MPFF)
Trial: 37728787
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg) in the morning (8.00-10.00 h)
Trial: 37728787
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg) in the evening (17.00-19.00 h)
Trial: 37728803
Drug: Sulforaphane (SFN)
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane (SFN) at a daily dose of 90 mg for 24 weeks
Trial: 37728907
Drug: Mirabegron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (50 mg/d)
Trial: 37728978
Drug: Thorough Epigenetic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thorough Epigenetic Marker Integration Solution (THEMIS) model using cfDNA features (methylated fragment ratio, chromosomal aneuploidy, fragment size index, fragment end motif).
Trial: 37728978
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of THEMIS model with serological indicators (pepsinogen, gastrin-17, Helicobacter pylori).
Trial: 37729132
Drug: Acupuncture (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (10 sessions of treatment)
Trial: 37729132
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 sessions of treatment)
Trial: 37729663
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg/day for 8 weeks
Trial: 37729663
Drug: Venlafaxine 225
RxNorm normalized name: venlafaxine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 225 mg/day for 8 weeks
Trial: 37730089
Drug: Lanadelumab 150
RxNorm normalized name: Lanadelumab 150 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanadelumab 150 mg every 4 weeks (Q4W) for patients aged 2 to <6 years